VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York. The presentation will be webcast at www.venatorx.com/UBS2018.
Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of antibiotic products to combat the increasing threat of carbapenem antibiotic resistance. VenatoRx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, and a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance. For more information, please visit www.venatorx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180517005187/en/
Contacts
VenatoRx Pharmaceuticals, Inc.
Heather Hunter, 610-644-8935
Vice President, Communications
hunter@venatorx.com
Source: VenatoRx Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180517005187/en
